baber/WOPTO huggingface dataset:
Patent NZ-500384-A (NZ)
Title: Choosing transmission protocol of serial half duplex communication between controllers and game machine
Inventor: IO HIDEAKI
IPC: G06F13/42
Filed: 1999-10-14
Abstract: A television game machine main unit communicates with connected game devices in half duplex serial mode, and includes a protocol controller and each game operation device connected to the television game machine unit via a serial port also has a protocol controller. The television game machine main unit when connected to a game operation device which has a unique identifier, combines a communication protocol that transmits and receives data for each character with a communication protocol which transmits or receives data for two or more characters in a row and switches the communication protocol which corresponds to that of the game operation device based on the identifier thereof to minimize the amount of information required between the television game machine main unit and the game operation device.
Patent NZ-512842-A (NZ)
Title: Benzimidazole vascular damaging agents
Inventor: DAVIS PETER DAVID
IPC: A61P19/02
Filed: 2000-01-14
Abstract: Use of vascular damaging agents characterised in formula I (5(6)0substituted benzimidazole-2-carbamates) for treating conditions associated with angiogenesis, where: - alk is an alkyl group - X is oxygen, sulfur, sulphonyl, carbonyl, thiocarbonyl, sulphonyloxy, NH, iminomethylene, N-hydroxyiminomethylene, N-alkoxyiminomethylene, dialkoxymethylene, 1,3-dioxolan-2-yl, 1,1-ethenyl, CHR3 or a bond; - R1 is hydrogen, alkylaminocarbonyl or alkoxycaronyl; - R2 is hydrogen, alkoxycarbonyl, cyanomethyl, cyanoethyl; alkoxymethyl or acetoxymethyl; - R3 is hydrogen, hydroxy, alkoxy or amino; and - A is a substituted aromatic, substituted heteroaromatic, substituted heterocycloalkyl, substituted alkyl or substituted cycloalkyl group.
Patent NZ-513418-A (NZ)
Title: Vaccine comprising proteins from mycobacterium paratuberculosis
Inventor: MURRAY ALAN
IPC: A61P31/04
Filed: 2001-08-07
Abstract: A vaccine comprising a secreted protein derived from Mycobacterium avium subsp. paratuberculosis which is substantially free of whole organisms of that species either dead or alive. This protein can be obtained from culturing microorganisms and then removing the microorganism cells by centrifugation and filtration, it can then be used in the preparation of a medicament for vaccination.
Patent NZ-514628-A (NZ)
Title: Use of inhibitors for inducing cancer cell death and tumor regression
Inventor: BISHOP WALTER R
IPC: A61K31/277
Filed: 2000-04-06
Abstract: Methods are provided for treating cancer, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an additional Ras signaling pathway inhibitor to induce cancer cell death and tumor regression.
Patent NZ-523544-A (NZ)
Title: Dried singulated crosslinked cellulose pulp fibers using jet drier
Inventor: YANCEY MICHAEL JAMES
IPC: D21H17/63
Filed: 2003-01-09
Abstract: A pulp product comprising singulated, crosslinked, and jet dried pulp fibers that has knot count equal to or less than 15%, wherein the pulp fibers are produced by a process comprising: introducing a wet pulp and air into a jet drier (20); treating the wet pulp with a crosslinker such as polyacrylic acid, glyoxal, malic acid or tartaric acid; thereafter drying the pulp in the jet drier (20) to form singulated pulp fibers; and removing the pulp from the jet drier and separating the pulp fibers from air. The process may further involve treating of wet pulp with surfactant or mineral particulate to reduce the knot content of the pulp fibers.  The process may still further involve treating of wet pulp with a hydrophobic material, a superplasticizer, a foam or a water reducing agent. Dried singulated cellulose pulp fibers produced by the above process have low knot count, a low fines count, as well improved knit, curl and twist and are useful for a wide product range from absorbent personal articles to a reinforcer in concrete.
Patent NZ-524554-A (NZ)
Title: Preparation of risperidone
Inventor: KROCHMAL BARNABA
IPC: C07D471/04
Filed: 2001-08-14
Abstract: The present invention is directed to the novel forms of risperidone, designated Form A, Form B and Form E. Methods for their preparation are also disclosed. The present invention also relates to processes for making risperidone. Pharmaceutical compositions containing the new forms of risperidone and methods of using them are also disclosed.
Patent NZ-531691-A (NZ)
Title: Storage wrap material
Inventor: HAMILTON PETER WORTHINGTON
IPC: C09J7/22
Filed: 2002-10-25
Abstract: Sheet-like materials suitable for use in the containment and protection of various items, as well as the preservation of perishable materials such as food items, comprise a sheet of material having a first active side and a second side. The first active side comprises a plurality of three-dimensional non-adherent protrusions extending outwardly from surrounding depressions and a pressure-sensitive adhesive composition coating on at least a portion of the depressions, wherein the adhesive composition coating has a thickness less than the height of the non-adherent protrusions and from about 0.00001 (0.00025 mm) to about 0.0002 inches (0.0051 mm) in thickness.
Patent NZ-533849-A (NZ)
Title: Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
Inventor: SEVERIN EVGENIY SERGEEVICH
IPC: A61K47/48
Filed: 2002-12-20
Abstract: Disclosed is a biological active polypeptide of the formula MYIEALDSYAC, capable of binding to receptors of the epidermal growth factor, causing cellular proliferation, and acting as vector molecule for the targeted delivery of anticancer drugs to cancer cells. A pharmaceutical composition having an anticancer effect is described to contain doxorubicin conjugated with a polypeptide of the formula MYIEALDSYAC.
Patent NZ-535232-A (NZ)
Title: Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
Inventor: BELL STANLEY C
IPC: A61P25/00
Filed: 2003-02-28
Abstract: Disclosed are compounds of formula (I) and processes and intermediates for making them, wherein the substituents are as described in the specification. Styryl benzylsulfones of the present invention are useful for the treatment of proliferative diseases such as cancer.
Patent NZ-537315-A (NZ)
Title: Calcitonin gene related peptide receptor antagonists
Inventor: CHATURVEDULA PRASAD V
IPC: C07D491/113
Filed: 2003-05-27
Abstract: A compound according to Formula (I) which acts as an antagonist of calcitonin gene-related peptide receptors ("CGRP-receptor"). The compound is used in treatment of neurogenic vasodilation, neurogenic inflammation, migraines, cluster headaches and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and other conditions which can be effected by the antagonism of CGRP-receptors.
Patent NZ-540293-A (NZ)
Title: Shelf stable, meltable, particulate food-grade plasticized savory product
Inventor: MAEGLI JACK WILLIAM
IPC: A23L1/164
Filed: 2003-10-24
Abstract: A savory, shelf-stable, particulate, meltable, food-grade plasticized composition is disclosed, having a water activity Aw of 0.60 or below. The composition is an oil-in-water emulsion of: a protein (preferably a casein such as sodium caseinate) that forms a thermally reversible meltable gel, plasticizer components to solubilize the protein, comprising a polyol plasticizer and a non-polyol plasticizer, a level of an edible oil component sufficient to provide proper texture, mouthfeel, and melt characteristics to the plasticized composition, and a savory flavoring component, and typically comprises 10-30 wt-% protein, 15-50 wt-% plasticizer component, including, based upon the total weight of the composition, 10-40 wt-% polyol plasticizer and 3-15 wt-% non-polyol plasticizer, 10-40 wt-% oil component, 5-25 wt-% moisture, and 10-40 wt-% flavour characterizing component. Also disclosed is a process for producing such a composition, which has a savory inclusion and is designed to be melted onto snack foods, etc. The process involves combining a protein that forms a thermally reversible meltable gel, plasticizer components including a polyol plasticizer and a non-polyol plasticizer, an edible oil, a savory inclusion, and water in an amount that provides a water activity Aw of 0.60 or less, heating the combined components under agitation to solubilize the protein, establish a homogenous oil-in-water emulsion, and provide a cooked gel product, casting and cooling the cooked gel product, and shredding or grinding the cast cooked gel product for consumption.
Patent NZ-540780-A (NZ)
Title: Heterocyclic piperidine derivatives as modulators of chemokine receptor CCR5
Inventor: CUMMING JOHN
IPC: C07D401/06
Filed: 2003-12-18
Abstract: Disclosed herein are heterocyclic piperidine derivative compounds of formula (I), wherein R1, R2, R3, R4, A, X, m and n are as defined in the specification; compositions comprising these compounds, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
Patent NZ-542607-A (NZ)
Title: Differential pulley having three gear ratios
Inventor: BOWMAN GEORGE
IPC: B66D3/06
Filed: 2005-09-22
Abstract: A pulley having three available gear ratios is disclosed. The pulley (110) has first (112) and second (114) pulley wheels with a pulley means acting between the wheels so that when equal force is applied to each wheel a low gear ratio is achieved. When one pulley wheel is prevented from rotating and a force is applied to the other wheel, a higher gear ratio is obtained. To achieve a third, even higher, ratio a force is applied to the first wheel and the second wheel is allowed to rotate. The means acting between the pulley wheels may prevent relative rotation of the wheels in one direction, while allowing rotation in the other direction.
Patent NZ-542733-A (NZ)
Title: Ostertagia vaccine
Inventor: GELDHOF PETER
IPC: C07K16/18
Filed: 2003-09-11
Abstract: The present invention relates to nucleic acid sequences encoding Ostertagia ostertagi proteins and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to Ostertagia ostertagi proteins and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic parts thereof. Also, the invention relates to the use of said proteins in vaccines and for the manufacture of vaccines. Moreover, the invention relates to the use of aid nucleic acid sequences, proteins or antibodies for diagnostic or vaccination purposes. Finally the invention relates to diagnostic kits comprising such nucleic acids, proteins or antibodies against such proteins.
Patent NZ-543188-A (NZ)
Title: Catalyst for synthesis of hydrocarbons from synthesis gas comprising cobalt, magnesium and optionally zirconium on a titania support, process of preparation of catalyst
Inventor: PANDULA SAMUEL
Filed: 2003-03-31
Abstract: Disclosed is a catalyst useful for the synthesis of hydrocarbons from synthesis gas, said catalyst comprising only from about 2 wt% to 50 wt% cobalt and from about 0.1 wt% to 15 wt% of magnesium or magnesium and zirconium, contained on a titania support, wherein the titania is in anatase phase only. Also disclosed is a process for preparation of a catalyst useful for synthesis of hydrocarbons from synthesis gas, said catalyst comprising only from about 2 wt% to 50 wt% cobalt and from about 0.1 wt% to 15 wt% of magnesium or magnesium and zirconium, contained on a titania support, said process comprising only: adding magnesium nitrate and cobalt nitrate in a range of about 1:1.5 to 1:3.0 (w/w) to distilled water in an amount of about 1.5 to 3.5 litres to obtain about 8 wt% to 15 wt% of solution; warming the solution at a temperature in the range of about 60 to 90 deg C under continuous stirring; adding about 8 wt% to 15 wt% of sodium carbonate solution dropwise to the warmed solution under continuous stirring till the pH of the solution is in the range of about 7.5 to 8.5, maintaining the temperature of the solution in the range of about 60 to 90 deg C; adding ground titania in a proportion in the range of about 1:4 to 1:6 (w/w) under stirring for a time period in the range of about 20 to 50 minutes; filtering the resultant solution under vacuum; washing the residue to remove nitrates; drying the filtrate at a temperature in the range of about 65 to 80 deg C for a time period in the range of about 6 to 15 hours; and cooling the dried filtrate.
Patent NZ-545478-A (NZ)
Title: Modulation of excitable tissue function by peripherally administered erythropoietin
Inventor: BRINES MICHAEL
IPC: A61P25/28
Filed: 2000-04-13
Abstract: Disclosed is a pharmaceutical composition packaged in a single dose vial adapted for modulation of excitable tissue, enhancement of cognitive function or delivery of compounds across the endothelial tight junctions which comprises, per dosage unit, an effective non-toxic amount within the range from about 150,000 to 500,000 Units of EPO, an EPO receptor activity modulator, an EPO-activated receptor modulator which are capable of activating EPR receptors of excitable tissue.
Patent NZ-546203-A (NZ)
Title: Modulators of P-Selectin Glycoprotein ligand 1
Inventor: LIN RONG-HWA
IPC: A61P35/00
Filed: 2004-09-09
Abstract: Disclosed are multimeric compounds that bind to at least two P-selectin glycoprotein ligand 1 (PSGL-l) proteins on the surface of a T cell or natural killer (NK) cell, wherein (A) the multimeric compound comprises two polypeptide chains, each of the polypeptide chains comprises (i) a binding domain that binds to PSGL-l, and (ii) a heterologous amino acid sequence, wherein the polypeptide chains are linked via the heterologous amino acid sequence to form the multimeric compound, and (B) when the multimeric compound is a homo-multimeric compound, the multimeric compound does not include an anti-PSGL-1 antibody or an antibody fragment that binds to PSGL-1. The binding of the multimeric compound to the at least two PSGL-1 proteins on the surface of the T cell or NK cell induces a signal transduction pathway that results in the death of the T cell or NK cell, thereby preventing or reducing T cell mediated or NK cell-mediated immune response.
Patent NZ-546440-A (NZ)
Title: Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
Inventor: DELUCA HECTOR F
IPC: A61P1/04
Filed: 2004-07-23
Abstract: Disclosed is the use of a vitamin D compound chosen from the following compounds 2-methylene-19-nor-l alpha-hydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-l ,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-l,24-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-24-homo-l,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-24-dihomo-l,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-24-trihomo-l,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-26,27-dimethyl-24-homo-l ,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-26,27-dimethyl-24-dihomo-l,25-dihydroxy-22dehydrovitamin D3; 2-methylene-19-nor-26,27-dimethyl-24-trihomo-l,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-26,27-diethyl-24-homo-l,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-26,27-diethy1-24-dihomo-l,25-dihydroxy-22dehydrovitaminD3; 2-methylene-19-nor-26,27-diethy1-24-trihomo-l ,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-26,27-dipropyl-24-homo-l,25-dihydroxy-22dehydrovitamin D3; 2-methylene-19-nor-26,27-dipropyl-24-dihomo-l ,25-dihydroxy-22-dehydrovitamin D3; 2-methylene-19-nor-26,27-dipropy1-24-trihomo-l ,25-dihydroxy-22dehydrovitamin D3; 2-methylene-19-nor-l alpha-hydroxyvitamin D3; 2-methylene-19-nor-l,25-dihydroxyvitamin D3; 2-methylene-19-nor-l,24-dihydroxyvitamin D3; 2-methylene-19-nor-24-homo-l,25-dihydroxyvitamin D3; 2-methylene-19-nor-24-dihomo-l,25-dihydroxyvitamin D3; 2-methylene-19-nor-24-trihomo-l,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-dimethyl-24-homo-l,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-dimethyl-24-dihomo-l ,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-dimethy1-24-trihomo-l ,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-diethyl-24-homo-l ,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-diethyl-24-dihomo-l,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-diethyl-24-trihomo-l ,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-dipropyl-24-homo-l,25-dihydroxyvitamin D3; 2-methylene-19-nor-26,27-dipropyl-24-dihomo-l ,25-dihydroxyvitamin D3; and 2-methylene-19-nor-26,27-dipropyl-24-trihomo-l ,25-dihydroxyvitamin D3 wherein the stereochemical center at carbon 20 may have the R or S configuration, in the manufacture of a medicament for the treatment of inflammatory bowel disease.
Patent NZ-552703-A (NZ)
Title: System and method for securing a credit account
Inventor: HARRIS DAVID N
IPC: G06F21/34
Filed: 2005-07-08
Abstract: A computer system for approving a commercial transaction between a user with account information and a merchant is disclosed. The computer system comprises a processing unit for processing data and code; and memory for storing the data and the code. The data and the code together includes a merchant communications module operative to facilitate a connection with the merchant for receiving a transaction approval request; activation data accessible to an account-holder and an authorization module responsive to the transaction approval request and operative to deny the transaction approval request if the account associated with the account-holder is deactivated. The activation data is indicative of the activation status of an account associated with the account-holder and with the account information. Prior to the user initiating the transaction with the merchant, the accountholder can modify the activation data to activate the account, thereby facilitating approval of the transaction approval request. Subsequent to approval of the transaction approval request, the accountholder can modify the activation data to deactivate the account such that subsequent transaction approval requests will be denied. Prior to the user initiating a future transaction using the account information, the account-holder can again modify the activation data to facilitate approval of a transaction approval request associated with the future transaction, thereby allowing the card-holder to deactivate the account between each future transaction. Each time the account is activated, the account remains activated indefinitely until the account is deactivated; and each time the account is activated, the duration that the account is activated is determined at the time the account is deactivated. The computer for approving a commercial transaction between a user with account information and a merchant can further comprise an account-holder communications module operative to facilitate a separate connection with the account-holder for verifying the transaction approval request. The authorization module is further operative to transmit an approval to the merchant only if the transaction approval request is verified by the account-holder.
Patent NZ-553205-A (NZ)
Title: System and method for dynamically adjusting patient therapy
Inventor: CONDURSON JOSEPH
IPC: G16H70/60
Filed: 2005-08-23
Abstract: A system for managing medication delivery to a patient comprises a communication system, the communication system configured to provide two way transmission of information over the communication system and a medication delivery device having a processor and a memory associated with the processor for storing programs for operating the processor to control the medication delivery device. The medication delivery device also includes a communication means, an input device for entering medication delivery parameters for a specific patient, and a display, all in operable communication with the processor. The medication delivery device capable of communicating over the communication system through its communication means. At least one server is operably connected to the communication system and is configured to access a database representative of at least one institutionally determined rule regarding medication delivery parameters. The medication delivery parameters are entered into the medication delivery device using the input device are communicated to the server and the server compares the communicated medication delivery parameters to information stored in the database of at least one institutionally determined rule to determine if the communicated medication delivery parameters fall within a range of values indicated as acceptable by the at least one institutionally determined rule. If the comparison indicates that the communicated medication delivery parameters do not fall within a range of values indicated as acceptable; the at least one server provides an alert to a caregiver.
Patent NZ-566627-A (NZ)
Title: Tamper evidencing band having loop at one end that distal strip of band can pass through and be attached to another portion of band strip
Inventor: MROCKI DION
IPC: A45C13/18
Filed: 2006-10-12
Abstract: A tamper evidencing band (100) for encircling an article includes an elongate strip. The band is provided with a loop. The loop is such that attempted opening or removal of the loop will be evidenced by the band. The strip has a portion distal from the loop which is insertable through the loop. Attachment means, typically a covered adhesive layer is provided to selectively attach the distal portion onto another portion of the strip to encircle the article whereby attempted removal of the attachment will be evidenced by the band. The tamper evidencing band may be provided as a flat strip with the loop unformed. Alternatively, the tamper evidencing band may be provided in kit form with a separate buckle to define the loop.
Patent NZ-570124-A (NZ)
Title: Use of a TPO peptide comprising the amino acid sequence IEGPTLRQ(2-Nal)LAAR(Sar) in the treatment of anemia
Inventor: MACDONALD BRIAN R
IPC: A61K38/18
Filed: 2006-02-14
Abstract: Disclosed is the use of an effective amount of a TPO peptide compound in the preparation of a medicament for preventing and/or treating anaemia. The disclosed TPO peptide compound comprises the following structure: IEGPTLRQ(2-Nal)LAAR(Sar).
Patent NZ-571810-A (NZ)
Title: Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
Inventor: GILBARD JEFFERY P
IPC: A01N65/00
Filed: 2007-04-12
Abstract: Disclosed are methods and compositions for the treatment of infection or infectious colonization of the eyelid and/or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders. The active ingredients of the invention are tea tree oil and linalool oil combined with a surfactant and membrane permeabiliser.
Patent NZ-579543-A (NZ)
Title: Anti-glypican 3 antibody
Inventor: NAKANO KIYOTAKA
IPC: C07K16/18
Filed: 2005-07-08
Abstract: Disclosed is a specific anti-glypican 3 antibody comprising three heavy chain CDRs and three light chain CDRs as defined in the specification. The disclosed antibody is capable of binding an epitope comprising the amino acid sequence GNSQQATPKDNEISTFHNLGNVHSPLK and is used in the treatment of cancer, in particular hepatoma.